(Bloomberg) -- Guardant Health Inc. is exploring an acquisition of cancer diagnostics and testing firm NeoGenomics Inc., according to people familiar with the matter.
Most Read from Bloomberg
Wall Street Titans Warn of the Next Big Risks for Investors
An Unapologetic Old Boys’ Network Is Costing Australia Billions
The Unstoppable Appeal of Highway Expansion
The Country That Makes Breakfast for the World Is Plagued by Fire, Frost and Drought
HSBC Bets Big on China as Pressure Mounts in London
The U.S.-listed companies have held discussions about a possible deal, the people said, asking not to be identified as the details aren’t public. Deliberations are ongoing and there’s no certainty they’ll lead to an offer from Guardant, the people said.
Representatives for Guardant and NeoGenomics couldn’t immediately be reached for comment.
NeoGenomics, which has a market value of $5.9 billion, provides diagnostic services to oncologists, pathologists, pharma companies and academic centers to aid in the treatment of cancers. Its larger peer Guardant has a market value of $12.7 billion.
Any deal would add to $446 billion of transactions in the global health-care industry this year, according to data compiled by Bloomberg. That’s up more than 86% on the same period in 2020 and makes it already the sector’s third-busiest year on record for dealmaking, the data show.
This week, Merck & Co. agreed to buy Acceleron Pharma Inc. for about $11.5 billion, building out its portfolio of therapies to treat rare diseases.
Most Read from Bloomberg Businessweek
‘Most Americans Today Believe the Stock Market Is Rigged, and They’re Right’
Atlanta’s Wealthiest and Whitest District Wants to Secede
The Left-for-Dead Hospital That Got a Second Chance for $1
A Tiny Piece of Plastic Is Helping Farmers Use Far Less Water
The Energy Future Needs Cleaner Batteries
©2021 Bloomberg L.P.
